Education
About Us
Working with TipRanks
Follow Us
Lenz Therapeutics, Inc. (LENZ)
:LENZ
LENZ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$16.54 - $38.93
Previous CloseN/A
Volume24.39K
Average Volume (3M)364.71K
Market Cap
$860.51M
Enterprise Value$614.42M
Total Cash (Recent Filing)$209.52M
Total Debt (Recent Filing)$1.05M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Nov 05, 2025EPS Estimate
-0.69Last Dividend Ex-Date
Mar 22, 2024Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding28,522,097
10 Day Avg. Volume465,442
30 Day Avg. Volume364,713
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)3.01
Price to Sales (P/S)0.00
P/FCF Ratio-10.26
Enterprise Value/Market Cap0.71
Enterprise Value/Revenue121.28
Enterprise Value/Gross Profit123.20
Enterprise Value/Ebitda-9.93
Forecast
1Y Price Target
$49.00Price Target Upside52.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Commercial Launch StrategyThe company has activated its branded commercial launch plan with its 88-member sales force and is planning to distribute samples to targeted optometrist offices.
Product DifferentiationVizz is the only eye drop approved that is not based on pilocarpine but on aceclidine, improving near vision without impacting distant vision.
Bears Say
Early Launch MetricsEarly launch metrics may face interpretability issues due to limitations around reporting of e-pharmacies.
Product Label WarningsThe label includes warnings for blurred vision, potential dim or dark vision, and caution for night driving and activities in poor illumination.
LENZ Therapeutics News
LENZ FAQ
What was Lenz Therapeutics, Inc.’s price range in the past 12 months?
Lenz Therapeutics, Inc. lowest stock price was $16.54 and its highest was $38.93 in the past 12 months.
What is Lenz Therapeutics, Inc.’s market cap?
Lenz Therapeutics, Inc.’s market cap is $860.51M.
When is Lenz Therapeutics, Inc.’s upcoming earnings report date?
Lenz Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2025 which is in 89 days.
How were Lenz Therapeutics, Inc.’s earnings last quarter?
Lenz Therapeutics, Inc. released its earnings results on Jul 30, 2025. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.61 by $0.08.
Is Lenz Therapeutics, Inc. overvalued?
According to Wall Street analysts Lenz Therapeutics, Inc.’s price is currently Undervalued.
Does Lenz Therapeutics, Inc. pay dividends?
Lenz Therapeutics, Inc. pays a Notavailable dividend of $7.21 which represents an annual dividend yield of N/A. See more information on Lenz Therapeutics, Inc. dividends here
What is Lenz Therapeutics, Inc.’s EPS estimate?
Lenz Therapeutics, Inc.’s EPS estimate is -0.69.
How many shares outstanding does Lenz Therapeutics, Inc. have?
Lenz Therapeutics, Inc. has 28,522,097 shares outstanding.
What happened to Lenz Therapeutics, Inc.’s price movement after its last earnings report?
Lenz Therapeutics, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.61. Following the earnings report the stock price went down -2.873%.
Which hedge fund is a major shareholder of Lenz Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LENZ
LENZ Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.00 (52.55% Upside)
$49.00 (52.55% Upside)
Blogger Sentiment
Bullish
LENZ Sentiment 70%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $32.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.3%
Last 30 Days ▲ 18.3%
Last 30 Days ▲ 18.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.50%
12-Months-Change
Fundamentals
Return on Equity
-26.25%
Trailing 12-Months
Asset Growth
7.25%
Trailing 12-Months
Company Description
Lenz Therapeutics, Inc.
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
LENZ Company Deck
LENZ Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presents a strong and positive outlook for LENZ Therapeutics, with significant progress in financial strength, pre-launch activities, and commercial readiness. Despite potential regulatory and economic challenges, the company appears well-prepared for the upcoming launch of LNZ100.View all LENZ earnings summariesLENZ Stock 12 Month Forecast
Average Price Target
$49.00
▲(52.55% Upside)
Technical Analysis
Prothena
―
Rocket Pharmaceuticals
―
Replimune Group
―
Immunome
―
Bicara Therapeutics Inc.
―
Ownership Overview
20.01% Insiders
6.06% Mutual Funds
0.32% Other Institutional Investors
65.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---